Join our family of curious Kansas Citians

Discover unheard stories about Kansas City, every Thursday.

Thank you for subscribing!

Check your inbox, you should see something from us.

Sign Me Up

Excuse the interruption.

Like what you see? For more stories like this, sign up for our newsletter. It drops in your inbox every Thursday.

Thank you for subscribing!

Check your inbox, you should see something from us.

Sign Me Up
Hit enter to search or ESC to close

Costs may limit use of meningitis B vaccine

Share this story

Financial considerations might influence use of a newly approved vaccine targeted at a strain of bacterial meningitis that often strikes college campuses, according to speakers at an event Thursday in Kansas City, Mo., sponsored by the Mid America Immunization Coalition (MAIC).

The drug in question is Pfizer’s Trumenba, which gained approval from the U.S. Food and Drug Administration in late October. It is the first vaccine aimed at preventing a type of bacterial meningitis known as strain B, a potentially life-threatening disease that attacks the lining surrounding the brain and spinal cord.

But the keynote speaker at the event, Dr. William Atkinson, said that meningitis B is extremely rare, with only about 250 cases in the United States last year.

Therefore, he said, the question is whether it will make fiscal sense for the government to recommend widespread use of the vaccine when it affects relatively few people.

“It is hard to justify economically to vaccinate millions of people to prevent 250 cases,” Atkinson said, “particularly when a lot of those cases are happening in babies, where the vaccine is not licensed yet.”

The FDA approved the drug for use in people ages 10 to 25.

An expert in vaccines, Atkinson is a former official with the U.S. Centers for Disease Control and Prevention and is now associate director for immunization education at the Immunization Action Coalition in St. Paul, Minn.

He expects the Advisory Committee on Immunization Practices, which is part of the CDC, to make a decision about the recommended usage of Trumenba at its February meeting in Atlanta.

Atkinson said indications are that the committee will make a fairly narrow recommendation on populations that should be vaccinated, including certain immune-suppressed individuals and people in areas that have experienced an outbreak. He does not expect the recommendation to cover college students.

Outbreaks of the strain occurred last year at Princeton University in New Jersey and at the University of California – Santa Barbara.

One Kansas man, Andy Marso, who has become an advocate for meningitis vaccination, contracted meningitis B a decade ago while a student at the University of Kansas.

Marso attended Thursday’s meeting to be recognized as one of MAIC’s 2014 Immunization Heroes for his advocacy work, particularly on behalf of a new Missouri law – enacted in July – requiring that all college students living on campus at public colleges and universities be vaccinated against meningitis.

(Marso is now a reporter for the KHI News Service, which is a partner in the Heartland Health Monitor, a reporting collaborative that includes KCPT and KCUR.)

The disease claimed the front half of both Marso’s feet and all of his fingers, except for his right thumb, when it compromised blood flow to his extremities.

Marso expressed concern that the three-dose regimen might prove too expensive for patients, with indications that it will cost more than the roughly $100 per dose it costs for vaccines for other strains of meningitis.

“There is going to be an issue of cost – no doubt about it,” he said.

Atkinson said insurance would likely cover populations included in recommendations from the CDC, but that it could be an out-of-pocket expense for others, such as parents who are sending their children to college.

Marso said his illness cost his father’s health insurance $2 million in the first year, including 140 days in the hospital and eight inpatient surgeries.

He said he expects to testify at the CDC committee meeting in February, and he said he realized government officials must make a cost-benefit analysis as part of their recommendation on who should receive the vaccination.

But in weighing the scope of their recommendations, he said he hoped the committee would consider the pain and suffering that go along with the after-effects of the disease.

“I hope they also account for people like me who are going to have ongoing medical costs for the rest of their lives because of this,” he said. “That is something that needs to be considered.”

Mike Sherry is a health reporter with Heartland Health Monitor, a reporting collaboration among KCUR Public Radio, KCPT Public Television, KHI News Service and Kansas Public Radio.

Major Funding for Health coverage on KCPT provided by Assurant Employee Benefits and the Health Care Foundation of Greater Kansas City.

Like what you are reading?

Discover more unheard stories about Kansas City, every Thursday.

Thank you for subscribing!

Check your inbox, you should see something from us.

Enter Email
Power Kansas City journalists to tell stories you love, about the community you love. Donate to Flatland.

Tags:

Leave a Reply

Your email address will not be published.